Fig. 3From: Elevated serum OX40L is a biomarker for identifying corticosteroid resistance in pediatric asthmatic patientsThe change of serum OX40L level after ICS therapy in SSA (a) and SRA (b) asthmatic patients. c The reduction in serum OX40L after ICS treatment was compared between SSA group and SRA group. **P < 0.01; ***P < 0.001. SSA: steroid-sensitive asthma; SRA: steroid-resistant asthmaBack to article page